Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with abnormal progenitor self-renewal and defective white blood cell differentiation. Its pathogenesis comprises subversion of transcriptional regulation, through mutation and by hijacking normal chromatin regulation. Kat2a is a histone acetyltransferase central to promoter activity, that we recently associated with stability of pluripotency networks, and identified as a genetic vulnerability in AML. Through combined chromatin profiling and single-cell transcriptomics of a conditional knockout mouse, we demonstrate that Kat2a contributes to leukemia propagation through preservation of leukemia stem-like cells. Kat2a loss impacts transcription factor binding and reduces t...
Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream tre...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
Competing Interest Statement: VH-H is co-Founder and CSO of Axovia Therapeutics. SP is the CEO of No...
Funder: Isaac Newton Trust; FundRef: http://dx.doi.org/10.13039/501100004815Funder: Associazione Ita...
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with abnormal progenitor self...
© 2020, Domingues et al. Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with...
KAT2A is a histone acetyltransferase recently identified as a vulnerability in at least some forms o...
Acute myeloid leukemia (AML) is one of the most lethal blood malignancies but in lack of therapies t...
Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine...
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells ...
Acute myeloid leukemia (AML) is one of the most lethal blood malignancies but in lack of therapies t...
Transcription factors form highly regulated and complex networks. In Acute Myeloid Leukaemia, driver...
The current paradigm on leukemogenesis indicates that leukemias are propagated by leukemic stem cell...
Cell fate transitions in mammalian stem cell systems have often been associated with transcriptional...
SummaryAcute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstr...
Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream tre...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
Competing Interest Statement: VH-H is co-Founder and CSO of Axovia Therapeutics. SP is the CEO of No...
Funder: Isaac Newton Trust; FundRef: http://dx.doi.org/10.13039/501100004815Funder: Associazione Ita...
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with abnormal progenitor self...
© 2020, Domingues et al. Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with...
KAT2A is a histone acetyltransferase recently identified as a vulnerability in at least some forms o...
Acute myeloid leukemia (AML) is one of the most lethal blood malignancies but in lack of therapies t...
Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine...
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells ...
Acute myeloid leukemia (AML) is one of the most lethal blood malignancies but in lack of therapies t...
Transcription factors form highly regulated and complex networks. In Acute Myeloid Leukaemia, driver...
The current paradigm on leukemogenesis indicates that leukemias are propagated by leukemic stem cell...
Cell fate transitions in mammalian stem cell systems have often been associated with transcriptional...
SummaryAcute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstr...
Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream tre...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
Competing Interest Statement: VH-H is co-Founder and CSO of Axovia Therapeutics. SP is the CEO of No...